GlassScriptPhysician profile
Vijaya P Samuel
NPI 1104810803
$7,503.96
in general payments reported to CMS, 2019-2025
48 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $428 · 2021: $872 · 2022: $1,211 · 2023: $1,402 · 2024: $1,423 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,052.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,395.25 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Pfizer INC. | $854.27 | 2019-2025 | |
| Amgen INC. | $782.07 | 2019-2025 | Evenity, Otezla, Prolia |
| Novo Nordisk INC | $753.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $533.66 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $364.91 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Eisai INC. | $236.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $177.63 | 2019-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $176.12 | 2019-2025 | |
| Amarin Pharma, INC. | $161.03 | 2019-2022 | |
| Boston Scientific Corporation | $157.18 | 2019-2025 | Watchman Flx, General - Pain Management |
| Radius Health, INC. | $154.57 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.47 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Sumitomo Pharma America, INC. | $139.39 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.37 | 2019-2024 | Xifaxan |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $116.84 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $112.25 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Ardelyx, INC. | $104.50 | 2024-2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $95.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.21 | 2022-2023 | |
| Exact Sciences Corporation | $73.20 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $59.19 | 2020-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $58.96 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $50.83 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $50.67 | 2021 | |
| Ibsa Pharma INC. | $48.84 | 2022-2025 | Tirosint, Licart, Tirosint |
| Allergan, INC. | $41.43 | 2020 | |
| Cequr Corporation | $39.83 | 2023-2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $38.95 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $37.65 | 2019-2021 | |
| Dexcom, INC. | $34.89 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $33.92 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $27.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.07 | 2019 | |
| Merz Pharmaceuticals, LLC | $25.25 | 2025 | Xeomin |
| Globus Medical, INC. | $23.39 | 2025 | Senza |
| Vital Connect, INC | $21.30 | 2025 | Vitalpatch Rtm |
| Dynavax Technologies Corporation | $19.64 | 2024 | Heplisav-B |
| Corcept Therapeutics | $17.34 | 2023 | Korlym |
| Electromed, INC. | $14.82 | 2025 | Smartvest |
| Mylan Specialty L.P. | $14.21 | 2024 | Yupelri |
| Amneal Pharmaceuticals LLC | $13.31 | 2022 | |
| Medtronic Vascular, INC. | $11.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $11.35 | 2021 | |
| Sanofi Pasteur INC. | $11.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.23 | 2019 | |
| Endogastric Solutions, INC | $6.81 | 2022 | |
| Vivus LLC | $3.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijaya Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.